VivoSim Labs, INC.
VIVSNasdaq
$0.58
↓ -5.6%Jul 17 close · end-of-day
Price
1Y↓ -68.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.5M
Enterprise Value
-$3.5M
P/E
—
P/S
11.4
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$131,000.00
Net Income (TTM)
-$13.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-8768.7%
Net Margin
-10567.2%
ROE
1259.6%
ROIC
—
Debt / Equity
—
Net Cash
$5.0M
Return 1Y
-68.9%
Company profile
Organovo Holdings, Inc. focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells. The company is developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases.
- CEO
- Keith Murphy
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- organovo.com
Earnings
VIVS Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$40,000.00↓ -21.6%
Diluted EPS-$2.20↓ -144.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.5M | $370,000.00 | $109,000.00 | $144,000.00 | $131,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.8M | -$11.5M | -$17.7M | -$15.1M | -$12.6M | -$11.5M |
| Net income | -$16.8M | -$11.4M | -$17.3M | -$14.7M | -$2.5M | -$13.8M |
| Diluted EPS | — | -$1.32 | -$1.98 | -$19.25 | -$1.70 | -$5.35 |
| Operating cash flow | -$13.3M | -$8.5M | -$12.4M | -$14.7M | -$9.5M | -$10.8M |
| Free cash flow | -$13.7M | -$8.9M | -$12.8M | -$14.7M | -$9.5M | -$10.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -765.3% | -4792.2% | -13840.4% | -8761.1% | -8768.7% |
| Net margin | — | -763.2% | -4664.6% | -13459.6% | -1727.8% | -10567.2% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39,000.00 | $30,000.00 | $24,000.00 | $51,000.00 | $37,000.00 | $28,000.00 | $26,000.00 | $40,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.4M | -$2.6M | -$3.5M | -$3.2M | -$2.9M | -$2.6M | -$2.8M | -$3.2M |
| Net income | -$3.3M | -$2.5M | -$3.4M | $6.9M | -$2.8M | -$2.5M | -$2.7M | -$5.8M |
| Diluted EPS | -$2.74 | -$1.68 | -$2.28 | $5.00 | -$1.14 | -$0.98 | -$1.03 | -$2.20 |
| Operating cash flow | -$3.0M | -$2.6M | -$1.8M | -$2.0M | -$3.9M | -$2.4M | -$2.3M | -$2.2M |
| Free cash flow | -$3.0M | -$2.7M | -$1.8M | -$2.0M | — | — | -$2.3M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -8682.1% | -8693.3% | -14450.0% | -6184.3% | -7878.4% | -9410.7% | -10576.9% | -7967.5% |
| Net margin | -8574.4% | -8496.7% | -14362.5% | 13435.3% | -7683.8% | -9089.3% | -10350.0% | -14410.0% |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.